十氢-1,5-萘啶 | 933687-81-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 十氢-1,5-萘啶
• 英文名称: decahydro-1,5-naphthyridine
• 英文别名: 1,5-diaza-cis-decalin；1,5-diaza-decalin；1,5-diazadecalin；decahydro-[1,5]naphthyridine；1,5-Naphthyridin；1,2,3,4,4a,5,6,7,8,8a-decahydro-1,5-naphthyridine
• CAS: 933687-81-1
• 化学式: C₈H₁₆N₂
• mdl: MFCD08703351
• 分子量: 140.228
• InChiKey: RQPDLNSKAAOHTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  十氢-1,5-萘啶 在 (PhIO)n 作用下， 生成 2-吡咯烷酮
  参考文献：
  名称：

  Comments on ‘Unusual oxidative rearrangement of 1,5-diazadecalin’

  摘要：

  Oxidation of cis or trans 1,5-diazadecalin with (PhlO)(n) yields 2-pyrolidinone and not 1,6-diaza-2,7-cyclodecadione, as reported. This is shown by a comparison of the NMR data of the reaction product with those of 2-pyrrolidinone and 1,6-diaza-2,7-cycloc ecadione. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.01.062
• 作为产物：
  描述：

  1,5-萘啶 在 Rh/Al₂O₃ 氢气 作用下， 20.0 ℃ 、6.89 MPa 条件下， 以95%的产率得到十氢-1,5-萘啶
  参考文献：
  名称：

  Synthesis and conformational properties of N-monoalkyl 1,5-diaza-cis-decalins

  摘要：

  N-Monoalkyl 1,5-diaza-cis-decalins were synthesized in high yield and purity by derivatization of tetrahydronaphthyridine followed by reduction to the saturated system. The position of the conformational equilibrium between the chair-chair inversion forms of a series of four N-monoalkyl of 1,5-diaza-cis-decalins was measured and was directly related to the size of the N-alkyl group. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)01344-2

文献信息

• [EN] HDAC INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA HDAC ET SES UTILISATIONS
  申请人：ENVIVO PHARMACEUTICALS INC

  公开号：WO2009137503A1

  公开（公告）日：2009-11-12

  Inhibitors of histone deacetylase, including compounds having a diazabicyclo[2.2.1]heptan-2-yl moiety are described together with methods for treating various disorders with such compounds.

  抑制组蛋白去乙酰化酶的抑制剂，包括具有二氮杂双环[2.2.1]庚烷-2-基基团的化合物，以及使用这些化合物治疗各种疾病的方法被描述。
• [EN] BICYCLIC INHIBITORS OF PAD4<br/>[FR] INHIBITEURS BICYCLIQUES DE PAD4
  申请人：PADLOCK THERAPEUTICS INC

  公开号：WO2017100594A1

  公开（公告）日：2017-06-15

  The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

  本发明提供了用作PAD4抑制剂的化合物、其组合物以及治疗与PAD4相关疾病的方法。
• HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME
  申请人：EA PHARMA CO., LTD.

  公开号：US20160332999A1

  公开（公告）日：2016-11-17

  The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.

  本发明提供了一种由公式(I)表示的化合物： 其中，每个符号如说明书中所定义，或者其药用可接受的盐。该化合物具有优越的TRPA1拮抗剂活性，并且可以提供一种用于预防或治疗涉及TRPA1拮抗剂和TRPA1的疾病的药物。
• Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase
  申请人：Forum Pharmaceuticals, Inc.

  公开号：US20170000749A1

  公开（公告）日：2017-01-05

  This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

  这份披露涉及用于抑制组蛋白去乙酰化酶和治疗认知障碍或缺陷的化合物。更具体地，该披露提供了公式（I）的化合物 其中 Q、J、L和Z如规范中所定义。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS DE L'HISTONE DÉSACÉTYLASE
  申请人：ENVIVO PHARMACEUTICALS INC

  公开号：WO2009137499A1

  公开（公告）日：2009-11-12

  Compounds which are histone deacetylase inhibitors and their use in treating various disorders, including Alzheimer's Disease.

  组合物是组蛋白去乙酰化酶抑制剂，用于治疗各种疾病，包括阿尔茨海默病。